Drugs / TMB-380
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT05275998 | Jul 2022 → Nov 2024 | HIV infectious disease | TaiMed Biologics Inc. | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT07215468 | Dec 2025 → Aug 2027 expected | HIV infectious disease | TaiMed Biologics Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 11 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMB-380 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215468 ↗ |
| Known as | VRC-07-523LS | “TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV.” NCT05275998 ↗1“VRC07-523LS” NCT07215468 ↗ |
| Action | Inhibit | “Both interfere with HIV entry.” NCT07215468 ↗ |
| Modality | Monoclonal antibody | “TMB-380, aka VRC-07-523LS is a monoclonal antibody” NCT05275998 ↗ |
| Route | Intravenous | “to be given intravenously” NCT07215468 ↗ |